Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99

O. Pagani; D. Klingbiel; T. Ruhstaller; F. Nolè; S. Eppenberger; C. Oehlschlegel; J. Bernhard; P. Brauchli; D. Hess; C. Mamot; E. Munzone; B. Pestalozzi; M. Rabaglio; S. Aebi; K. Ribi; C. Rochlitz; K. Rothgiesser; B. Thürlimann; R. von Moos; K. Zaman; A. Goldhirsch

doi:10.1093/annonc/mdw622

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99

O. Pagani
, D. Klingbiel
, T. Ruhstaller
, F. Nolè
, S. Eppenberger
, C. Oehlschlegel
, J. Bernhard
, P. Brauchli
, D. Hess
, C. Mamot
, E. Munzone
, B. Pestalozzi
, M. Rabaglio
, S. Aebi
, K. Ribi
, C. Rochlitz
, K. Rothgiesser
, B. Thürlimann
, R. von Moos
, K. Zaman

A. Goldhirsch

Careum School of Health

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	305-312
Journal	Annals of Oncology
Volume	28
Issue number	2
DOIs	https://doi.org/10.1093/annonc/mdw622
Publication status	Published - 1 Feb 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/annonc/mdw622Licence: Other

https://linkinghub.elsevier.com/retrieve/pii/S0923753419322288

Cite this

Pagani, O., Klingbiel, D., Ruhstaller, T., Nolè, F., Eppenberger, S., Oehlschlegel, C., Bernhard, J., Brauchli, P., Hess, D., Mamot, C., Munzone, E., Pestalozzi, B., Rabaglio, M., Aebi, S., Ribi, K., Rochlitz, C., Rothgiesser, K., Thürlimann, B., von Moos, R., ... Goldhirsch, A. (2017). Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Annals of Oncology, 28(2), 305-312. https://doi.org/10.1093/annonc/mdw622

@article{d3984b37f67c4821b4f2ee08b387e5ca,

title = "Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99",

author = "O. Pagani and D. Klingbiel and T. Ruhstaller and F. Nol{\`e} and S. Eppenberger and C. Oehlschlegel and J. Bernhard and P. Brauchli and D. Hess and C. Mamot and E. Munzone and B. Pestalozzi and M. Rabaglio and S. Aebi and K. Ribi and C. Rochlitz and K. Rothgiesser and B. Th{\"u}rlimann and \{von Moos\}, R. and K. Zaman and A. Goldhirsch",

year = "2017",

month = feb,

day = "1",

doi = "10.1093/annonc/mdw622",

language = "English",

volume = "28",

pages = "305--312",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "2",

}

Pagani, O, Klingbiel, D, Ruhstaller, T, Nolè, F, Eppenberger, S, Oehlschlegel, C, Bernhard, J, Brauchli, P, Hess, D, Mamot, C, Munzone, E, Pestalozzi, B, Rabaglio, M, Aebi, S, Ribi, K, Rochlitz, C, Rothgiesser, K, Thürlimann, B, von Moos, R, Zaman, K & Goldhirsch, A 2017, 'Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99', Annals of Oncology, vol. 28, no. 2, pp. 305-312. https://doi.org/10.1093/annonc/mdw622

TY - JOUR

T1 - Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99

AU - Pagani, O.

AU - Klingbiel, D.

AU - Ruhstaller, T.

AU - Nolè, F.

AU - Eppenberger, S.

AU - Oehlschlegel, C.

AU - Bernhard, J.

AU - Brauchli, P.

AU - Hess, D.

AU - Mamot, C.

AU - Munzone, E.

AU - Pestalozzi, B.

AU - Rabaglio, M.

AU - Aebi, S.

AU - Ribi, K.

AU - Rochlitz, C.

AU - Rothgiesser, K.

AU - Thürlimann, B.

AU - von Moos, R.

AU - Zaman, K.

AU - Goldhirsch, A.

PY - 2017/2/1

Y1 - 2017/2/1

U2 - 10.1093/annonc/mdw622

DO - 10.1093/annonc/mdw622

M3 - Article

SN - 0923-7534

VL - 28

SP - 305

EP - 312

JO - Annals of Oncology

JF - Annals of Oncology

IS - 2

ER -